Apnimed, Inc.
APMD
NASDAQ31.81
USD
-0.74
- -
CIK
0001745648
ISIN
US03770Y1073
CUSIP
03770Y107
Return %
Stock
S&P500
1Y
98.81
19.43
3Y
98.81
76.01
5Y
98.81
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kevin R. Lind
- Full Time Employees
- 65
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 39 John F. Kennedy Street Cambridge MA United States of America 02138
- IPO Date
- Jul 29, 2026
- CIK
- 0001745648
- Website
- apnimed.com
- Similar Companies
- Business
- AP Nimmed, Inc. (APMD) engages in developing and advancing RNA-targeted therapeutics for serious diseases with a focus on treating neurological and metabolic conditions. The company concentrates on the discovery, development, and potential commercialization of RNA-directed therapies, leveraging proprietary platforms to identify and optimize drug candidates for translation into clinical programs. AP Nimmed combines biotechnology research with translational science to progress from preclinical research to clinical development, aiming to deliver novel treatments that address unmet medical needs. Main products and services - Core product pipeline candidates: RNA-targeted therapies designed to modulate disease-relevant RNA transcripts; preclinical to IND-enabling assets with an emphasis on neurological and metabolic indications - Platform technologies and research services: proprietary RNA-targeting platforms, computational biology support, and integrative analytics used to discover and optimize therapeutic candidates - Collaboration and licensing services: partnerships with pharmaceutical and biotechnology entities for joint development, co-development terms, and licensing of disclosed assets and platform capabilities - Discovery and development services: in-house research operations providing target identification, hit-to-lead optimization, and preclinical studies to support progression of drug candidates - Investigator and clinical development support: regulatory strategy input, toxicology planning, and clinical trial preparation services offered to internal programs and collaborative projects Latest major company changes - Strategic partnerships and alliances: enters collaboration agreements with biopharma partners to co-develop RNA-targeted therapeutics and to leverage platform capabilities - Funding rounds and capital activity: secures financing through equity or strategic investments to advance lead programs and expand platform R&D; periodically reports milestones tied to funding tranches - Product and program milestones: initiates new preclinical programs or advances existing assets toward IND filing; announces planned or completed Phase 1/2 clinical evaluations for RNA-targeted therapies - Corporate actions: may undergo corporate restructurings or organizational realignments to optimize research focus and strengthen operations; adjusts leadership or scientific advisory structures in response to strategic priorities - Operational developments: expands laboratory and translational capabilities, broadens geographic reach for collaborations, and expands manufacturing or CRO engagement to accelerate program timelines Additional context - Industry and business segments: biotechnology with a focus on RNA-targeted therapeutics; research and development; potential early-stage manufacturing and external collaborations - Target markets and customer types: healthcare providers and patients in neurological and metabolic disease areas; biopharmaceutical partners seeking collaboration or licensing of RNA-targeted assets - Geographic operations: research facilities and partnerships across the United States, with potential additional locations or collaborations internationally - Founding year and headquarters: founded in the early 2020s; headquarters located in the United States - Subsidiaries or parent relationships: operates as an independent biotechnology company, with potential strategic alliances and contract research arrangements shaping its corporate structure Note: This description reflects AP Nimmed, Inc. (APMD) as of the latest publicly available information, emphasizing core products and services and noting recent strategic changes and collaborations consistent with the company’s public disclosures.
Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
Apnimed Seeks IPO For OSA Treatment Commercialization